OakChart

Nuwellis Inc

NUWEHealthcare·Medical Devices·USA·Nano·NASD·Nov 11 • 3:59 PM ET

5.53+0.29 (5.53%)
2026-11-12 06:44 CET
Market cap
2.99 USD m
Revenue, TTM
9.01 USD m
Net income, TTM
-11.32 USD m
Free cash flow, TTM
-12.59 USD m
EPS diluted, TTM
-1,224.57
P/E
-
Compare

Price

NUWE against its 20, 50 and 200-day averages
2050200missearnings
0.00250.00500.00750.0012.0M24.0MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26NUWEclose 5.5320-day 4.9450-day 6.10200-day 209.935.53

99.6% under the 52-week high of 1,556.07 on 27 Jan 2026. 52-week low 2.52 on 26 Oct 2026. Last 15 sessions, 183.3% high to low

Volume 0.05× normal · the line is the 50-bar volume average

Profile

NUWE
52-week range, 0% of the way up
2.521,556

Nuwellis, Inc. operates as a medical device company. It engages in the provision of products for the treatment of fluid overload. The firm's products include Aquadex FlexFlow System, which provides an ultrafiltration for the removal of salt and water in patients with hypervolemia, or fluid overload. It operates through Cardiac and Coronary Disease Products segment. The company was founded by Crispin Marsh and William S. Peters in November 1999 and is headquartered in Eden Prairie, MN.

Employees38
IPOFeb 16, 2012
Beta0.01
ATR, 14d0.82
Rel volume0.05
Short float55.88%
Inst own1.65%

Snapshot

6 groups

Valuation

Index-
Market Cap2.99M
Enterprise Value-0.72M
Income-11.32M
Sales9.01M
Book/sh-32.20
Cash/sh7.26
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees38
IPOFeb 16, 2012

Ratios

P/E-
Forward P/E-
PEG-
P/S0.33
P/B-
P/C0.76
P/FCF-
EV/EBITDA-
EV/Sales-0.08
Quick Ratio1.54
Current Ratio1.97
Debt/Eq-
LT Debt/Eq-
Option/ShortNo / Yes

Earnings

EPS (ttm)-1224.57
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y94.09% 88.99%
Sales past 3/5Y-1.08% 2.14%
EPS Y/Y TTM88.88%
Sales Y/Y TTM8.36%
EPS Q/Q98.75%
Sales Q/Q14.14%
EarningsNov 12 BMO
EPS/Sales Surpr.- -

Ownership

Insider Own-
Insider Trans-
Inst Own1.65%
Inst Trans-
ROA-123.57%
ROE-609.44%
ROIC-
Gross Margin69.69%
Oper. Margin-142.87%
Profit Margin-125.57%
SMA2011.94%
SMA50-9.32%
SMA200-97.37%
Trades-

Technical

Shs Outstand0.54M
Shs Float0.35M
Short Float55.88%
Short Ratio0.24
Short Interest0.20M
52W High1556.07 -99.64%
52W Low2.52 119.05%
Volatility11.10% 20.53%
ATR (14)0.82
RSI (14)49.42
Beta0.01
Rel Volume0.05
Avg Volume821.08K
Volume39,995

Performance

Perf Week4.93%
Perf Month-1.06%
Perf Quarter-52.74%
Perf Half Y-98.30%
Perf YTD-98.99%
Perf Year-99.37%
Perf 3Y-100.00%
Perf 5Y-100.00%
Perf 10Y-100.00%
Recom1.00
Target Price145530.00
Prev Close5.24
Price5.53
Change %5.53%

Analyst ratings

latest 1 of 1
DateActionAnalystRating changeTargetImplied
Jul 29, 2024InitiatedRROTH MKMBuy$17+207.4%

Peers

Mkt cap
TickerCompanyMkt cap
CTSOCytosorbents Corp16.83M
OMOutset Medical Inc78.61M
AEMDAethlon Medical Inc8.87M
CVRXCVRx Inc19.95M
XAIRBeyond Air Inc4.38M
BAXBaxter International Inc13.63B
HSCSHeartSciences Inc11.40M
ICUSeaStar Medical Holding Corp10.21M
DXRDaxor Corp49.76M
FMSFresenius Medical Care AG ADR11.53B

News

latest 14 of 200
  • Nuwellis Secures Exclusive U.S. Distribution Rights for Zorro-Flow Pediatric Urine Collection System Supporting Non-invasive Urine Collection and Earlier Identification of Acute Kidney Injury in Neonates and Small Children (GlobeNewswire) +6.07%
  • Nuwellis Submits FDA 510(k) to Expand Aquadex SmartFlow Indication to Include Pediatric Patients Weighing 5 kg and Above (GlobeNewswire) -11.57%
  • Nuwellis to Report Third Quarter 2026 Financial Results on November 12 (GlobeNewswire) -10.83%
  • Nuwellis Announces Acceptance of Multicenter Pediatric Aquadex Study in Pediatric Nephrology (GlobeNewswire) +74.69%
  • Nuwellis to Convene Pediatric Medical & Nursing Advisory Board to Advance Development of Vivian Pediatric CRRT System (GlobeNewswire)
  • Nuwellis to Highlight Advancements in Fluid Management Across Pediatric Care, Critical Care, and Heart Failure at Leading October Medical Conferences (GlobeNewswire)
  • Nuwellis Reports 31 Aquadex Console Sales in 2026, Expanding Recurring Revenue Opportunity (InvestorsHub) +33.74%
  • Nuwellis Reports Strong Aquadex Console Adoption, with 31 Aquadex SmartFlow Consoles Sold Year-to-Date, Meaningfully Expanding Recurring Revenue Opportunity (GlobeNewswire)
  • Nuwellis Strengthens Organization with Appointment of Brian Johnson as Director of Quality and Regulatory Affairs (GlobeNewswire)
  • Nuwellis Advances Financial Efficiency Strategy with Improved Gross Margins (GlobeNewswire)
  • Nuwellis Expands Critical Care Portfolio Through Strategic Commercial Agreement with Atrility Medical (GlobeNewswire) -8.65%
  • Nuwellis Inc (NUWE) (Q2 2026) Earnings Call Highlights: Revenue Surges 14% and Installed Base ... (GuruFocus.com) -7.80%
  • Nuwellis Reports Second Quarter 2026 Financial Results and Business Highlights Focused on Double Digit Revenue Growth and Expanded Gross Margin (GlobeNewswire)
  • Nuwellis Accelerates Digital Transformation of the Aquadex Platform with EHR Connectivity and Enhanced User Interface (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-13-239.76--239.761.97--
2026Q12026-05-12-658.35-315-689.072.402.091
2025Q42026-03-10-472.5-491.4-472.442.422.311
2025Q32025-11-12176.4-176.642.22--
2025Q22025-08-14-19,212--19,2091.73--
2025Q12025-05-13-9,129-5,954-9,1131.902.501
2024Q42025-03-11-5,821-5,689-5,7672.322.462
2024Q32024-11-1123,020-16,93423,0752.372.362
2024Q22024-08-13-249,386-109,081-249,4612.192.002
2024Q12024-05-07-277,830-490,833-279,0991.862.001
2023Q42024-03-05-1,037,232-643,640-1,037,1302.552.573
2023Q32023-11-07-838,121-1,442,077-837,1672.412.293
2023Q22023-08-08-1,690,133-1,862,989-1,689,3642.082.193
2023Q12023-05-09-2,667,168-1,756,488-2,666,8581.832.343
2022Q42023-02-28-2,315,250-38,017,933-2,316,4722.342.213
2022Q32022-11-08-17,132,850-14,817,600-17,005,0482.072.293

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2018FY-58,538,781,000-56,996,824,500-58,564,647,0585.005.16
2019FY-12,919,095,000--12,916,872,3685.515.80
2020FY-494,074,350-453,325,950-494,022,9537.447.46
2021FY-132,895,350-136,291,035-131,727,5387.928.40
2022FY-38,687,828-75,037,253-38,654,0308.548.41
2023FY-5,334,336-5,649,210-5,333,6378.868.87
2024FY-111,264-309,648-105,9008.748.88
2025FY-7,998-8,102-7,9988.278.16
2026FY--721.35--9.87
2027FY--198.45--11.05
2028FY-9,393--35.89
2029FY-18,787--49.45

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-05-121102.512.512.51
2026Q3S2026-03-101002.312.312.31
2026Q3S2026-01-301002.312.312.31
2026Q3S2026-01-291002.312.312.31
2026Q3S2025-11-181002.312.312.31
2026Q3R2026-05-12101-122.85-122.85-122.85
2026Q3R2026-03-10110-103.95-103.95-103.95
2026Q3R2026-01-29110-110.25-110.25-110.25
2026Q3R2025-11-18100-119.7-119.7-119.7
2026Q3E2026-05-12101-122.85-122.85-122.85
2026Q3E2026-03-10110-103.95-103.95-103.95
2026Q3E2026-01-29110-110.25-110.25-110.25
2026Q3E2025-11-18100-119.7-119.7-119.7
2026Q2S2026-05-121102.422.422.42

Estimate history

EPS, annual-391360145777.98-58564647057.845-12916872367.947-494022952.898-131727538.286-38654029.594-5333636.81-105899.667-7995.21-1224.5674
Period201720182019202020212022202320242025TTM
EPS, quarterly-249461.17623075.237-5766.957-9113.486-19209.034176.636-472.437-689.072-239.695
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual3.5534.9985.5117.4417.9218.5438.8648.748.279.01
Period201720182019202020212022202320242025TTM
Sales, quarterly2.1942.3672.3221.9041.7252.2172.4242.4031.969
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual000000000.0050.064
Period201720182019202020212022202320242025MRQ
Shares, quarterly00000.0020.0040.0050.0080.064
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue9.018.278.748.868.547.927.445.515.00
Cost of Goods Sold Incl. D&A2.733.153.063.883.793.433.382.663.67
Gross Profit6.285.125.684.984.754.494.062.851.33
Selling, General and Administrative Excl. Other19.1616.2316.6622.6121.9324.0221.0920.9618.36
Research and Development4.162.713.215.424.344.983.674.673.05
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-12.88-11.11-10.99-17.63-17.17-19.53-17.03-18.11-17.04
Interest Expense6.0810.555.613.489.25--0.000.00
Unusual Expense-7.63-4.13-5.510.00-11.830.00--0.00
Net Income Before Taxes-11.32-17.52-11.16-20.20-14.52-19.55-15.83-18.11-17.03
Income Taxes0.000.010.010.010.010.010.010.010.01
Consolidated Net Income-11.32-17.52-11.16-20.21-14.53-19.55-15.84-18.11-17.03
Net Income From Continuing Operations-11.32-17.52-11.16-20.21-14.53-19.55-15.84-18.11-17.03
Net Income-11.32-17.52-10.62-22.63-14.53-19.63-17.59-22.62-17.03
EPS (Recurring)-827.24-9,315.70-144,380.97-5,333,638.20-60,685,791.84-131,729,414.13-494,046,616.12-12,927,428,571.43-58,564,730,841.90
EPS (Basic, Before Extraordinaries)-1,224.57-7,995.21-105,899.67-5,333,636.81-38,654,029.59-131,727,538.29-494,022,952.90-12,916,872,367.95-58,564,647,057.85
EPS (Diluted)-1,224.57-7,995.21-105,899.67-5,333,636.81-38,654,029.59-131,727,538.29-494,022,952.90-12,916,872,367.95-58,564,647,057.85
EBITDA-12.40-10.69-10.68-17.27-16.80-19.04-16.65-17.87-16.80
Non-Operating Income (Expense)0.000.01-0.080.910.07-0.021.200.000.01
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.090.100.380.530.680.960.981.101.65
Price To Sales Ratio0.060.150.170.130.220.991.540.380.55
Gross Margin69.6961.9664.9456.2255.6656.7054.5251.7326.57
Operating Margin-142.87-134.29-125.72-198.89-200.99-246.51-228.84-328.54-340.86
Net Margin-125.57-211.81-121.56-255.27-170.02-247.81-236.43-410.51-340.78
Shares Outstanding0.060.010.000.000.000.000.000.000.00
Market Capitalization2.992.994.861.081.1312.0119.074.023.51

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue1.972.402.422.221.731.902.322.37
Cost of Goods Sold Incl. D&A0.470.720.770.770.770.840.970.71
Gross Profit1.501.681.651.450.961.071.351.66
Selling, General and Administrative Excl. Other4.676.254.104.143.864.133.743.19
Research and Development0.941.730.880.600.680.550.830.49
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-3.17-4.57-2.44-2.70-2.91-3.06-2.39-1.53
Interest Expense6.080.000.000.0010.55-0.000.00
Unusual Expense-4.41-0.03-0.03-3.16-0.90-0.04-0.91-3.88
Net Income Before Taxes-4.83-4.54-2.420.47-12.55-3.01-1.472.36
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-4.83-4.54-2.420.47-12.55-3.01-1.472.36
Net Income From Continuing Operations-4.83-4.54-2.420.47-12.55-3.01-1.472.36
Net Income-4.83-4.54-2.420.47-12.55-3.01-1.472.36
EPS (Recurring)-393.02-691.84-476.81-656.71-20,173.11-9,198.15-8,277.57-3,517.07
EPS (Basic, Before Extraordinaries)-239.69-689.07-472.44176.64-19,209.03-9,113.49-5,766.9623,075.24
EPS (Diluted)-239.69-689.07-472.44176.64-19,209.03-9,113.49-5,766.9623,075.24
EBITDA-3.13-4.53-2.08-2.65-2.86-2.99-2.30-1.46
Non-Operating Income (Expense)0.010.00-0.010.000.010.010.010.01
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.020.030.020.020.010.050.080.10
Price To Sales Ratio0.060.250.340.340.230.470.430.18
Gross Margin76.0870.0868.2365.1855.5456.0458.3569.96
Operating Margin-160.94-190.10-100.78-121.65-168.46-160.71-102.80-64.72
Net Margin-245.15-188.89-99.8821.15-727.65-158.25-63.2299.62
Shares Outstanding0.060.010.010.000.000.000.000.00
Market Capitalization2.992.772.934.574.884.114.862.22

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments1.085.093.8018.3124.2014.441.285.4815.60
Short Term Receivables1.491.731.951.410.750.910.800.790.55
Inventories1.911.722.002.662.842.961.801.661.59
Other Current Assets0.700.320.460.400.330.240.160.200.14
Total Current Assets5.198.868.2122.7728.1318.544.048.1317.86
Net Property, Plant & Equipment0.660.991.441.882.271.461.430.540.57
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Intangible Assets---0.000.000.000.000.000.00
Other Assets0.270.020.120.020.020.020.130.110.02
Total Assets6.129.869.7724.6730.4220.015.608.7818.45
Short Term Debt Incl. Current Port. of LT Debt0.260.240.220.220.190.230.190.000.00
Accounts Payable1.981.642.382.251.411.101.491.130.86
Other Current Liabilities0.790.680.582.221.702.261.681.711.23
Total Current Liabilities3.032.563.174.693.313.583.352.842.09
Long Term Debt0.070.310.540.760.980.110.260.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.390.472.846.870.180.000.000.000.13
Total Liabilities3.493.336.5612.324.473.693.612.842.22
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.010.000.220.000.000.000.000.000.00
Common Equity2.626.532.9912.3625.9516.321.995.9416.24
Total Shareholders Equity2.636.533.2112.3625.9516.321.995.9416.24
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity2.636.533.2112.3625.9516.321.995.9416.24
Total Liabilities & Stockholders Equity6.129.869.7724.6730.4220.015.608.7818.45
Book Value Per Share490.1919,745.33243,647.8710,667,361.80114,017,977.39276,155,017.77592,261,904.7616,060,228,304.9081190000000
Tangible Book Value Per Share490.1919,745.33243,647.8410,667,391.81114,017,664.89276,155,017.77592,261,904.7616,060,232,364.7281190000000
Full-Time Employees383859707064662446
Price to Book Ratio-0.170.740.140.080.461.172.020.593,101,877,571.34
Return on Assets-219.26-113.73-117.35-52.73-77.55-123.65-251.97-125.09-103.23
Return on Equity-382.55-229.24-259.62-75.84-92.53-173.00-457.08-153.62-144.83
Return on Invested Capital-649.65-163.30-538.19-110.73-72.61-96.40-804.71-286.93-82.41
Quick Ratio1.082.791.964.297.654.350.672.287.78
Current Ratio1.713.462.594.868.505.171.202.868.54

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-11.32-17.52-11.16-20.21-14.53-19.55-15.84-18.11-17.03
Depreciation0.370.420.310.360.370.490.380.240.23
Other Funds (Non Cash)-0.716.551.573.33-1.591.330.191.512.09
Funds from Operations-11.66-10.56-9.29-16.52-15.75-17.74-15.27-16.36-14.71
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-0.80-0.25-0.30-1.420.60-0.10-1.30-0.000.15
Cash from Operating Activities-12.46-10.81-9.59-17.94-15.15-17.84-16.57-16.37-14.56
Capital Expenditures-0.21-0.09-0.06-0.25-0.12-0.22-0.30-0.49-0.20
Net Assets From Acquisitions-0.160.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.030.000.00
Purchase or Sale of Investments0.000.000.000.5814.85-15.500.000.000.00
Purchase of Investments0.000.000.000.000.00-18.850.000.000.00
Sale Or Maturity of Investments0.000.000.000.5814.853.350.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-0.38-0.09-0.060.3314.73-15.72-0.27-0.49-0.20
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock12.366.9410.963.719.4527.9030.0412.664.65
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock12.366.9410.963.719.4527.9030.0412.664.65
Proceedsfrom Stock Options3.002.942.403.599.4527.9025.9212.664.65
Issuance or Reduction of Debt, Net0.000.000.00-0.03-0.03-0.03-0.020.000.00
Change in Long Term Debt0.000.000.00-0.03-0.03-0.03-0.020.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.00-0.03-0.03-0.03-0.020.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities12.366.9410.963.689.4227.8730.0212.664.65
Exchange Rate Effect0.060.06-0.02-0.01-0.01-0.00-0.02-0.01-0.00
Net Change in Cash-0.42-3.901.29-13.948.99-5.7013.16-4.20-10.12
Free Cash Flow-12.59-10.90-9.65-18.09-15.27-18.06-16.87-16.86-14.76
Preferred Dividends (Cash Flow)----0.00---0.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments3.922.081.083.094.452.56
Short Term Receivables1.541.561.491.141.191.54
Inventories1.741.781.912.192.031.75
Other Current Assets0.690.410.700.780.740.27
Total Current Assets7.905.835.197.208.426.12
Net Property, Plant & Equipment0.530.600.660.760.760.86
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.100.11----
Other Assets0.600.420.270.020.020.02
Total Assets9.136.966.127.989.207.01
Short Term Debt Incl. Current Port. of LT Debt0.200.270.260.260.250.24
Accounts Payable2.902.431.982.673.011.73
Other Current Liabilities0.911.040.790.600.640.78
Total Current Liabilities4.013.733.033.523.892.75
Long Term Debt0.000.000.070.130.190.25
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities7.160.560.390.4214.070.43
Total Liabilities11.174.293.494.0718.163.42
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.010.010.010.010.010.00
Common Equity-2.062.662.623.91-8.963.58
Total Shareholders Equity-2.042.672.633.91-8.963.58
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity-2.042.672.633.91-8.963.58
Total Liabilities & Stockholders Equity9.136.966.127.989.207.01
Book Value Per Share-32.20318.02490.19901.87-5,354.1010,822.42
Tangible Book Value Per Share-33.79304.64490.19901.87-5,354.1010,822.42
Full-Time Employees--38---
Price to Book Ratio-0.171.041.121.17-0.541.15
Return on Assets-123.57-272.76-219.26-225.22-190.75-144.12
Return on Equity--609.44-382.55-467.14--440.77
Return on Invested Capital--170.14-89.8011.58--78.67
Quick Ratio1.541.091.081.421.641.59
Current Ratio1.971.561.712.042.162.23

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-4.83-4.54-2.420.47-12.55-3.01
Depreciation0.040.040.250.040.050.07
Other Funds (Non Cash)1.690.76-0.17-2.989.670.03
Funds from Operations-3.10-3.75-2.34-2.47-2.83-2.91
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.070.64-0.69-0.680.740.38
Cash from Operating Activities-3.17-3.11-3.03-3.15-2.10-2.54
Capital Expenditures-0.01-0.120.01-0.10-0.000.00
Net Assets From Acquisitions0.00-0.160.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.01-0.280.01-0.10-0.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Change in Capital Stock5.034.391.051.894.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock5.034.391.051.894.000.00
Proceedsfrom Stock Options-4.344.391.051.890.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow-0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities5.024.391.051.894.000.00
Exchange Rate Effect0.000.000.060.00-0.01-0.00
Net Change in Cash1.841.00-1.90-1.361.89-2.54
Free Cash Flow-3.18-3.14-3.02-3.25-2.10-2.54

Revenue breakdown

Electromedical & Electrotherapeutic Apparatus2024: 8.74M 2025: 8.27M
United States2024: 8.74M 2025: 8.27M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3055.88%0.2M0.4M890.01K
2026-10-152.86%0.0M0.3M474.54K
2026-09-305.37%0.0M0.3M482.04K
2026-09-151.22%0.0M0.3M382.28K
2026-08-315.47%0.0M0.3M375.88K
2026-08-143.03%0.0M0.3M328.27K
2026-07-3130.13%0.1M0.4M253.62K
2026-07-1531.72%0.0M0.0M11.35K
2026-06-3021.12%0.0M0.0M8.00K
2026-06-151.22%0.0M0.0M4.34K
2026-05-2913.99%0.0M0.0M256
2026-05-151.34%0.0M0.0M194
2026-04-302.90%0.0M0.0M276
2026-04-152.06%0.0M0.0M6.79K
2026-03-311.40%0.0M0.0M6.85K
2026-03-131.32%0.0M0.0M6.81K
2026-02-271.53%0.0M0.0M6.69K
2026-02-131.39%0.0M0.0M6.68K
2026-01-3022.90%0.0M0.0M6.62K
2026-01-150.57%0.0M0.0M281

Option chain

expiry 2026-11-12
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-238-KCurrent report2026-10-22SEC
2026-09-18SCHEDULE 13G/ASEC
2026-08-26EFFECTEffectiveness filing by commission orderSEC
2026-08-26424B3SEC
2026-08-268-KCurrent report2026-08-25SEC
2026-08-18S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-138-KCurrent report2026-08-13SEC
2026-08-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-07SCHEDULE 13GSEC
2026-08-06SCHEDULE 13GSEC
2026-08-05SCHEDULE 13GSEC
2026-08-038-KCurrent report2026-07-31SEC
2026-08-03424B5SEC
2026-07-248-KCurrent report2026-07-24SEC
2026-07-07DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-07-07SEC
2026-07-013Initial statement of beneficial ownership of securities2026-06-30SEC
2026-06-26PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-07-24SEC
2026-06-248-KCurrent report2026-06-23SEC
2026-06-188-KCurrent report2026-06-16SEC
2026-06-108-KCurrent report2026-06-08SEC
2026-06-08424B4SEC
2026-06-05S-1MEFA new registration statement filed under Rule 462(b) to add securities to a prior related effective registration statement filed on Form S-1SEC
2026-06-04EFFECTEffectiveness filing by commission orderSEC
2026-06-04CORRESPSEC
2026-06-04S-1/ASEC
2026-06-02FWPFiling under Securities Act Rule 163/433 of free writing prospectuses.SEC
2026-05-29S-1/ASEC
2026-05-28SDSpecialized Disclosure ReportSEC
2026-05-22S-1General form of registration statement for all companies including face-amount certificate companiesSEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
SABBY MANAGEMENT, LLC4.49%
StoneX Group Inc.1.04%
GEODE CAPITAL MANAGEMENT, LLC0.62%
UBS Group AG0.09%
Tower Research Capital LLC0.04%
MORGAN STANLEY0.01%
SBI Securities Co., Ltd.0.00%
Caitong International Asset Management Co., Ltd0.00%

Funds

Fund% owned
Fidelity Extended Market Index Fund0.62%
Fidelity Series Total Market Index Fund0.00%

OakChart. NUWE. Cached 15 minutes.

Some panels did not load: insider.